New Patent Could Be Worth $6 A Share To Amgen
New Patent Could Be Worth $6 A Share To Amgen
Geoffrey Porges and his team of analysts at Sanford C. Bernstein took another look at the patent Amgen was issued last week on the top-selling drug Enbrel, used to treat rheumatoid arthritis, psoriasis, and other immune diseases. They found that the patent was more valuable than it initially appeared, because [...]